10 patients with HCV-induced vasculitis refractory to HCV therapy received 1.5×106 IU subcutaneous (SC) IL-2 daily for 5 days, followed by three 5 day courses of 3×106 IU/day at weeks 3, 6 and 9. Here, IL2 is linked to vasculitis.